Q3 2021 Investor Relations Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
Neuroscience
Ophthalmology
Respiratory & Allergy
Oncology: Solid Tumors
Hematology
Biosimilars
Global Health
Abbreviations
CRM
IHD
aflibercept - VEGF inhibitor
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT04864834 Mylight (CSOK583A12301)
Aflibercept BioS
Phase 3
460
Best-corrected visual acuity (BCVA) will be assessed using the ETDRS testing
charts at an initial distance of 4 meters. The change from baseline in BCVA in
letters is defined as difference between BCVA score between week 8 and baseline
Arm 1 Biological: SOK583A1 (40 mg/mL)
Arm 2 Biological: Eylea EU (40 mg/mL)
Patients with neovascular age-related macular degeneration
Target Patients
Read-out Milesstone(s)
2023
Publication
tbd
131 Investor Relations | Q3 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation